Edwards Lifesciences Corp

Overview

Edwards Lifesciences Corp. is a global medical-technology company focused on structural heart disease. Its core businesses include transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), and surgical structural heart products, including its SAPIEN valve family and mitral and tricuspid systems.[1]+3

The company operates worldwide, with business organized across the United States, Europe, Japan, and the rest of the world. Its stated Credo is to provide innovative solutions for people fighting cardiovascular disease and improve quality of life worldwide.[2][5]

For fiscal 2025, Edwards reported net sales of approximately $6.1 billion. The company’s careers page describes a workforce of more than 16,000 team members and a global footprint of more than 50 offices and plants.[6][7] [1]+6

Products & services

Edwards’ current product portfolio includes transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), and surgical heart products. Its TAVR offering centers on the SAPIEN family of transcatheter valves for aortic stenosis. SAPIEN 3 Ultra RESILIA is a balloon-expandable valve with a cobalt-chromium frame, a trileaflet RESILIA bovine-pericardial valve, and PET skirts.[3][8]

TMTT products include PASCAL, a transcatheter leaflet-approximation system for mitral or tricuspid regurgitation; EVOQUE, a transcatheter bioprosthetic tricuspid valve replacement system; and SAPIEN M3, a transseptal mitral replacement therapy.[4]+3 Surgical products include the INSPIRIS RESILIA aortic valve, MITRIS RESILIA mitral valve, and KONECT RESILIA aortic valved conduit. KONECT is a preassembled conduit for complex combined procedures, and INSPIRIS incorporates VFit technology.[12]+3

For the six months ended June 30, 2026, sales were $2,455.6 million for TAVR, $373.7 million for TMTT, and $560.3 million for Surgical, respectively 12.8%, 49.6%, and 8.2% above the prior-year period. These groups represented approximately 72.4%, 11.0%, and 16.5% of total sales, respectively, calculated from reported group sales and total sales.[16]+3 [3]+16

Geographic presence

Edwards Lifesciences’ FY2025 sales were $6,067.6 million. The United States accounted for $3,543.1 million (58.4%), Europe $1,517.5 million (25.0%), Japan $354.7 million (5.8%), and Rest of World $652.3 million (10.7%). Percentages are calculated from reported regional sales and rounded, so they sum to 99.9%.[20]

For the six months ended June 30, 2026, sales totaled $3,389.6 million: $1,941.1 million (57.3%) in the United States, $882.2 million (26.0%) in Europe, $187.0 million (5.5%) in Japan, and $379.3 million (11.2%) in Rest of World. Percentages are calculated from reported amounts.[21]

The FY2025 report lists operating locations in the United States (Irvine, California; Draper, Utah; and Naperville, Illinois), Costa Rica (Cartago), Switzerland (Nyon), the Czech Republic (Prague), Ireland (Shannon/Limerick), Spain (Valencia), Singapore, Japan (Tokyo), China (Shanghai), and Israel (Caesarea). The listed functions vary by site and include manufacturing, administration, marketing, distribution, research and development, and corporate headquarters activities. This location schedule does not provide employee counts by geography.[20] [20][21]

Business segments

Edwards Lifesciences reports four **geographic** segments in its 2025 Form 10-K: United States, Europe, Japan, and Rest of World. Their approximate shares of 2025 segment net sales were 58.4%, 25.0%, 5.8%, and 10.8%, respectively. The company does not describe different therapeutic or product focuses for these regions; each is part of its global cardiovascular business.[20]+2

Separately, the company discloses sales by product category. In 2025, Transcatheter Aortic Valve Replacement (TAVR) accounted for about 74.0% of sales; Surgical Structural Heart, 17.0%; and Transcatheter Mitral and Tricuspid Therapies, 9.1%. These are product categories, not the company’s reportable geographic segments. TAVR covers catheter-delivered aortic valve replacement; Surgical Structural Heart includes surgical tissue-valve replacement and repair; and Mitral and Tricuspid Therapies include repair and replacement treatments for those valves.[23]+3 [20]+9

Company history

Edwards Lifesciences traces its origins to 1958, when engineer Miles “Lowell” Edwards began developing an artificial heart with surgeon Albert Starr. Their collaboration produced the Starr–Edwards heart valve, implanted for the first time on September 21, 1960; Edwards Laboratories was incorporated that year to manufacture and market the valve.[5][25]

The company expanded its heart-valve technologies with the Carpentier–Edwards PERIMOUNT tissue valve, which entered clinical use in 1981. After becoming part of Baxter in 1985, Edwards separated from Baxter and began trading as an independent public company on the New York Stock Exchange in 2000.[26][27]

A major subsequent development was its move into transcatheter aortic-valve treatment: the SAPIEN valve received European approval in 2007 and became the first catheter-based aortic heart valve approved in the United States in 2011. Edwards later broadened its structural-heart portfolio through acquisitions, including CardiAQ in 2015 and Valtech Cardio in 2017. In 2024, it completed the sale of its Critical Care product group.[28]+4 [5]+8

Sources

• Edwards Lifesciences Corp — Full financial report (2025 Y)
  11 citations

  [1][2][3][4][6][9][12][13][20][22][24]
• www.edwards.com[5]
• www.edwards.com[7]
• eifu.edwards.com[8]
• www.edwards.com[10]
• www.edwards.com[11]
• www.edwards.com[14]
• info.edwards.com[15]
• Edwards Lifesciences Corp — Full financial report (2026 Q 2)
  5 citations

  [16][17][18][19][21]
• Edwards Lifesciences Corp — Press release (2025 Y)[23]
• ir.edwards.com[25]
• ir.edwards.com[26]
• ir.edwards.com[27]
• ir.edwards.com[28]
• ir.edwards.com[29]
• ir.edwards.com[30]
• ir.edwards.com[31]
• ir.edwards.com[32]